Acute Intraprocedural Gastroparesis During Pulmonary Vein Cryoablation



Gastroparesia aguda intraprocedimiento durante crioablación de venas pulmonares

To the Editor.

Gastroparesis is a syndrome characterized by delayed gastric emptying in the absence of obstruction leading to epigastric discomfort, abdominal distention, nausea, and vomiting, although it can also be asymptomatic. One of the causes of acute gastroparesis, which is not widely reported and is unfamiliar to many cardiologists, is gastroparesis secondary to pulmonary vein (PV) cryoablation, a technique that is available at over 50% of Spanish electrophysiology laboratories. Based on a case of gastroparesis, we have reviewed this syndrome.

We report the case of a 59-year-old man, with a history of symptomatic paroxysmal atrial fibrillation despite the use of antiarrhythmic drugs, in whom we decided to perform PV




Figure 1. Image of fluoroscopy showing gastric bubble distension.

cryoablation. During the procedure, performed under sedation with remifentanil and propofol, we observed a small left atrium on angiography (37 mm in the previous echocardiogram) with 4 independent PVs. We decided to use a 28-mm second-generation Medtronic Arctic Front cryoballoon. Due to poor occlusion and poor temperatures, 4 applications were required to isolate the left upper PV. 2 applications for the left lower PV. and another 2 for the right upper PV. In the right lower PV, which was the smallest in terms of the balloon. 3 applications were initially performed with a minimum temperature of -36 °C; there was a transient loss of phrenic nerve capture during 1 application. The vein was finally isolated with a 23-mm balloon with a single application for 64 s at -60 °C. The total cryoablation time was 26 minutes. The mean minimum temperature reached in all applications was -40 ± 16 °C. No bonus applications were given after isolating the veins. On removal of the catheters, fluoroscopy revealed gastric dilation with air accumulation in the fundus (Figure 1). Although the patient only had abdominal distension with tympanism and flatulence, we decided to place him under observation in the coronary care unit for 6 hours. Treatment was started with prokinetics (metoclopramide and erythromycin), antisecretory drugs, and a nil per os diet for the first 24 hours. A nasogastric tube was not required. In the following 24 hours, the symptoms and radiological changes were resolved (Figure 2). The patient remains asymptomatic.

Several studies have related acute gastroparesis following ablation to injury to the nerve fibers that innervate the pyloric sphincter and the stomach. These nerves mainly travel with the left vagal trunk through the anterior part of the esophagus, close to the posterior wall of the left atrium and the ostium of the PVs. Application of heat or cold in the posterior wall of the left atrium may damage these perioesophageal nerves, whether transiently or permanently, and may lead to gastroparesis.

Of the few published cases of gastroparesis following PV ablation, the majority occurred in patients undergoing radio-frequency ablation. Symptoms appeared within a few hours of the procedure, and spontaneously resolved with medical treatment and observation.³

In the case of PV cryoablation, a study by Guiot et al.⁴ in 66 patients showed, using endoscopic assessment of gastric




Figure 2. Baseline: X-ray of abdomen with abundant air content in gastric bubble, loop of small intestine, and colon structure, with no radiological signs of obstruction. At 24 hours: normal luminogram.

motility as per protocol, that 9% of these patients had asymptomatic gastroparesis 24 hours after the procedure. In a subsequent analysis, only the onset of phrenic nerve paralysis during the procedure was associated with a higher risk of gastroparesis, although this was transient. A more recent observational study prospectively compared the frequency of onset of gastroparesis among 104 patients undergoing PV cryoablation or radiofrequency. Six cases were detected in the cryoablation group (5% of the sample). Only one case was detected in the radiofrequency group. The patients who received cryoablation and developed gastroparesis had smaller atria (36 \pm 2 mm) and lower mean temperatures were achieved (–51 \pm 2.3 °C). All these patients received medical treatment and none of them had residual symptoms at 6 months, with the exception of the patient with gastroparesis following radiofrequency.

We describe a complication of PV ablation that is not often associated with a history of PV cryoablation, particularly in cases of late onset and generally with good prognosis. Possible risk factors associated with cryoablation in our patient are low temperature, multiple applications, and the use of a large balloon in a small atrium. Ablation of the right lower PV was particularly complex, as it required 2 balloon sizes, and its anatomical relationship with the esophagus is unknown, as no imaging test was performed in advance, which could have been useful. Fluoroscopic observation of the stomach and distended intestinal loops is useful for the initial diagnosis. Confirmatory diagnosis could be obtained by means of gastric emptying scintigraphy in severe and/or uncertain cases, although this technique is generally unnecessary. Initial treatment is conservative with antisecretory drugs and prokinetics, and endoscopic treatment is reserved for more severe cases.

David Cordero Pereda,* M. Fe Arcocha Torres, José Miguel Ormaetxe Merodio, Larraitz Gaztañaga Arantzamendi, Estibaliz Zamarreño Golvano, and Jesús Daniel Martínez-Alday

Sección de Arritmias, Servicio de Cardiología, Hospital Universitario, Basurto, Bilbao, Spain

* Corresponding author:

E-mail address: davidcorderopereda@gmail.com

(D. Cordero Pereda).

Available online 3 March 2017

REFERENCES

- 1. Jung HK, Choung RS, Locke 3rd GR et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. *Gastroenterology*. 2009;136:1225–1233.
- Pedrote A, Fontenla A, García-Fernández J. Registro Español de Ablación con catéter.
 XV Informe Oficial de la Sección de Electrofisiología y Arritmias de la Sociedad Española de Cardiología (2015). Rev Esp Cardiol. 2016;69:1061–1070.
- 3. Garg L, Garg J, Gupta N, et al. Gastrointestinal complications associated with catheter ablation for atrial fibrillation. *Int J Cardiol.* 2016;224:424–430.
- Guiot A, Savouré A, Godin B, et al. Collateral nervous damages after cryoballoon pulmonary vein isolation. J Cardiovasc Electrophysiol. 2012;23:346–351.
- 5. Aksu T, Golcuk S, Guler TE, et al. Gastroparesis as a complication of atrial fibrillation ablation. *Am J Cardiol.* 2015;116:92–97.

http://dx.doi.org/10.1016/j.rec.2017.01.025 1885-5857/

© 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Successful Extracorporeal Membrane Oxygenation in a Patient With Fulminant Lupus Myocarditis



Oxigenador extracorpóreo de membrana eficaz en una paciente con miocarditis lúpica fulminante

To the Editor,

Fulminant lupus myocarditis (LM) is an uncommon heart manifestation of systemic lupus erythematosus (SLE).¹ Although extracorporeal membrane oxygenation (ECMO) is a standard therapy for patients with cardiogenic shock, its use in the context of SLE is anecdotal.² We describe an SLE patient with fulminant LM requiring ECMO.

A 26-year-old Filipino woman with a history of SLE was admitted to our center in January 2015 with fever and dyspnea. SLE had been diagnosed 4 years previously based on perimyocarditis, serositis, leucopenia, Raynaud's phenomenon, hypocomplementemia, and positive antinuclear, anti-Sm, and anti-RNP antibodies. She was treated with hydroxychloroquine and pulses of methylprednisolone and cyclophosphamide and received azathioprine as maintenance treatment. She showed a good clinical response and remained in remission for the next 4 years.

At the current admission, the patient reported a 6-day history of fever and worsening dyspnea. Six months previously, she had abandoned treatment. Physical examination revealed increased heart (110 bpm) and respiratory (26 pm) rates and unremarkable breath and heart sounds. Laboratory tests found a high erythrocyte sedimentation rate (60 mm/h; normal value, < 20) and normal

creatinine kinase but elevated troponin I (0.103 mg/L; normal value, < 0.05). Electrocardiogram showed sinus tachycardia, with no ST-segment changes, and transthoracic echocardiography found no dilated chambers and normal valve function and left ventricular ejection fraction (LVEF; 55%).

Treatment with prednisone (30 mg/d) and meropenem was instituted, but the patient continued to have recurrent fever and a tendency to hypotension. Blood tests showed elevated troponin I (1 ng/dL) and pancytopenia (leucocytes, 2.3×10^9 /L; hemoglobin, 6.7 g/dL; platelet count, 75×10^9 /L). A second echocardiogram showed biventricular global dysfunction (LVEF, 35%). Microbiological tests for bacteria, fungi, viruses, and mycobacteria were all negative. Subsequent investigations revealed a positive antinuclear titer (> 1:640), negative anti-DNA and antiphospholipid antibodies, and normal complement levels. Despite dobutamine infusion, diuretics, intravenous pulses of methylprednisolone (1 g/d for 5 days) followed by prednisone (60 mg/d), an intravenous pulse of cyclophosphamide (1 g), and empiric broadspectrum antibiotics (piperacillin/tazobactam and daptomycin), the patient developed respiratory distress with shock. Repeat echocardiography showed ventricular deterioration (LVEF, 20%) with a restrictive transmitral flow pattern, moderate mitral insufficiency, mild tricuspid insufficiency with mildly elevated pulmonary artery pressure, and a cardiac index of 2.0 L/m². Due to the clinical suspicion of recurrent acute LM, propensity for reversibility with immunosuppression, and given the life-threatening situation, ECMO was instituted and rituximab (2 doses of 1 g fortnightly) was added to the medical therapy.

After ECMO implementation and following high-intensity immunosuppression therapy, the patient showed progressive clinical improvement with hemodynamic stability. After a